Fair Value Measurements (Schedule of Financial Assets Measured At Fair Value On A Nonrecurring Basis) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges	$ (129,625)	$ (7,000)
Fair value, measurements, nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total income (expense) from assets	(150,804)
Fair value, measurements, nonrecurring | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total income (expense) from intangible assets	(129,625)
Fair value, measurements, nonrecurring | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset impairment charges	(4,892)
Total income (expense) from intangible assets	(16,287)
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0
Fair value, measurements, nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0
Certain segment intangible assets	0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	0
Fair value, measurements, nonrecurring | Significant Other Observable Inputs (Level 2) | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0
Certain segment intangible assets	0
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	45,522
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | U.S. Generic Pharmaceuticals
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certain segment intangible assets	45,522
Fair value, measurements, nonrecurring | Significant Unobservable Inputs (Level 3) | Astora
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Property, plant and equipment	0
Certain segment intangible assets	$ 0